The Precious Gift of More

People facing Alzheimer’s disease long for more time. More memories. More days of feeling like nothing has changed. But the heartbreaking reality is that all these things are stripped away, often with little warning.
That’s why the UW Initiative to End Alzheimer’s (IEA) is pioneering the most advanced research initiatives and treatments to give people and their families hope for the future.

Dr. Todd C. Flynn Scholarship Fund

Todd C. Flynn, PhD, led a vibrant life as a clinical and forensic psychologist, working with children, adolescents, families, veterans and enlisted folks throughout his career. His family has established a scholarship fund in his name that will help support the IEA Innovation Fund, which provides project funding for researchers from the Wisconsin Alzheimer’s Disease Research Center (ADRC) and Wisconsin Alzheimer’s Institute (WAI).

Announcing the IEA Innovation Fund

The UW Initiative to End Alzheimer’s (IEA) is pleased to announce the IEA Innovation Fund, providing project support for researchers from the Wisconsin Alzheimer’s Disease Research Center (ADRC) or Wisconsin Alzheimer’s Institute (WAI). The IEA Innovation Fund will help advance the University of Wisconsin–Madison’s Alzheimer’s disease researchers’ most promising ideas by providing an open door to funding opportunities that foster translational, innovative and inclusive advancements in Alzheimer’s disease research.

A closer look at lecanemab

In January, the U.S. Food and Drug Administration (FDA) approved Leqembi (lecanemab-irmb) via the Accelerated Approval pathway to treat Alzheimer’s disease. Nathaniel Chin, MD, recently interviewed Cynthia Carlsson, MD, MS, and Sterling Johnson, PhD, to inform people about the research behind the new Alzheimer’s treatment, the drug’s benefits and risks, and more.